-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca reports 44% confirmed response rate for ERAS-0015 in Phase 1 pancreatic cancer trial

PUBT·11/20/2026 12:01:44
Listen to the news
Erasca reports 44% confirmed response rate for ERAS-0015 in Phase 1 pancreatic cancer trial
  • Erasca reported updated Phase 1 results showing tumor responses to ERAS-0015 in advanced pancreatic, lung and biliary tract cancers.
  • Treatment was generally well tolerated, with mostly low-grade treatment-related adverse events and limited dose interruptions or reductions.
  • A first-line pancreatic cancer Phase 3 trial was accelerated to first-half 2027; a potentially registration-enabling previously treated lung cancer trial remains scheduled then.
  • A first-line lung cancer Phase 3 trial is planned for the second half of 2027 through the first half of 2028.
  • Preliminary ERAS-4001 results showed antitumor activity with favorable tolerability, supporting planned combination testing with ERAS-0015 in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611200700PRIMZONEFULLFEED9881854) on November 20, 2026, and is solely responsible for the information contained therein.